NO20070249L - Pyrrazolo-pyrimidin derivater - Google Patents

Pyrrazolo-pyrimidin derivater

Info

Publication number
NO20070249L
NO20070249L NO20070249A NO20070249A NO20070249L NO 20070249 L NO20070249 L NO 20070249L NO 20070249 A NO20070249 A NO 20070249A NO 20070249 A NO20070249 A NO 20070249A NO 20070249 L NO20070249 L NO 20070249L
Authority
NO
Norway
Prior art keywords
pyrrazolo
pyrimidine derivatives
compounds
well
regulation
Prior art date
Application number
NO20070249A
Other languages
English (en)
Norwegian (no)
Inventor
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20070249L publication Critical patent/NO20070249L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20070249A 2004-06-21 2007-01-15 Pyrrazolo-pyrimidin derivater NO20070249L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102837 2004-06-21
PCT/EP2005/006302 WO2005123738A1 (fr) 2004-06-21 2005-06-13 Derives de pyrrazolo-pyrimidine

Publications (1)

Publication Number Publication Date
NO20070249L true NO20070249L (no) 2007-02-15

Family

ID=34971089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070249A NO20070249L (no) 2004-06-21 2007-01-15 Pyrrazolo-pyrimidin derivater

Country Status (25)

Country Link
US (1) US7378417B2 (fr)
EP (1) EP1761541B1 (fr)
JP (1) JP4608542B2 (fr)
CN (1) CN100528876C (fr)
AR (1) AR049521A1 (fr)
AT (1) ATE383361T1 (fr)
AU (1) AU2005254657B2 (fr)
BR (1) BRPI0512330A (fr)
CA (1) CA2571487C (fr)
DE (1) DE602005004287T2 (fr)
DK (1) DK1761541T3 (fr)
ES (1) ES2299044T3 (fr)
HR (1) HRP20080070T3 (fr)
IL (1) IL179736A (fr)
MX (1) MXPA06014809A (fr)
MY (1) MY143368A (fr)
NO (1) NO20070249L (fr)
NZ (1) NZ551660A (fr)
PL (1) PL1761541T3 (fr)
PT (1) PT1761541E (fr)
RU (1) RU2378277C2 (fr)
SI (1) SI1761541T1 (fr)
TW (1) TWI301835B (fr)
WO (1) WO2005123738A1 (fr)
ZA (1) ZA200610102B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512966T1 (de) * 2005-02-11 2011-07-15 Hoffmann La Roche Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
ATE463495T1 (de) 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
CA2626789A1 (fr) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrimidinones en tant que modulateurs de caseine kinase ii (ck2)
AU2008279759A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
BRPI0914404A2 (pt) * 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
AR078171A1 (es) * 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
WO2012075393A2 (fr) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activateurs de la dégradation protéasomique et leurs utilisations
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
WO2012149157A2 (fr) 2011-04-26 2012-11-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
CA2868484A1 (fr) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derives d'acide salicylique utiles a titre d'activateurs de glucocerebrosidase
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
WO2014066743A1 (fr) 2012-10-25 2014-05-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
WO2014066795A1 (fr) 2012-10-25 2014-05-01 Bioenergenix Composés hétérocycliques pour l'inhibition de pask
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (fr) 2014-09-26 2016-03-30 Domain Therapeutics Pyrazoloquinazolinones et pyrroloquinazolinones substitués en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate du groupe II
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2016073889A1 (fr) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Imidazo[1,5-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux
EP3215511B1 (fr) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Pyrazolo(1,5-a)pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
WO2017066428A1 (fr) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Inhibiteurs de brd4-kinase à utiliser en tant qu'agents thérapeutiques anticancéreux
EA037941B1 (ru) 2015-12-18 2021-06-09 Янссен Фармацевтика Нв ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
KR20180133461A (ko) * 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
MX388912B (es) 2016-04-06 2025-03-20 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
WO2017176961A1 (fr) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Composés imidazo [1,5-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles médicaux
WO2017192930A1 (fr) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
WO2017192931A1 (fr) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. Imidazo[1,2-a]pyridines substituées, imidazo[1,2-a]pyrazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017212A (en) * 1986-03-20 1991-05-21 Takeda Chemical Industries, Ltd. Sulfonylurea compounds and herbicidal use
EP0729758A3 (fr) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
GB9712718D0 (en) * 1997-06-18 1997-08-20 Heights Design Production Ltd Binding apparatus
DK0891978T3 (da) * 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
PL354675A1 (en) * 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
EP1379511B1 (fr) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DERIVES DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ONE UTILISES COMME ANTAGONISTES DE MGLUR2(II)
KR20040111445A (ko) * 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine

Also Published As

Publication number Publication date
EP1761541B1 (fr) 2008-01-09
ZA200610102B (en) 2008-08-27
HRP20080070T3 (en) 2008-05-31
NZ551660A (en) 2009-08-28
AU2005254657A1 (en) 2005-12-29
PL1761541T3 (pl) 2008-06-30
MXPA06014809A (es) 2007-02-12
CA2571487C (fr) 2013-04-30
PT1761541E (pt) 2008-03-13
CN1964973A (zh) 2007-05-16
HK1105971A1 (zh) 2008-02-29
IL179736A0 (en) 2007-05-15
RU2006143571A (ru) 2008-07-27
BRPI0512330A (pt) 2008-02-26
RU2378277C2 (ru) 2010-01-10
DK1761541T3 (da) 2008-04-28
EP1761541A1 (fr) 2007-03-14
US20050282827A1 (en) 2005-12-22
WO2005123738A1 (fr) 2005-12-29
IL179736A (en) 2010-12-30
SI1761541T1 (sl) 2008-06-30
ES2299044T3 (es) 2008-05-16
CA2571487A1 (fr) 2005-12-29
DE602005004287T2 (de) 2008-12-24
MY143368A (en) 2011-04-29
TW200626598A (en) 2006-08-01
DE602005004287D1 (de) 2008-02-21
CN100528876C (zh) 2009-08-19
ATE383361T1 (de) 2008-01-15
JP4608542B2 (ja) 2011-01-12
JP2008503510A (ja) 2008-02-07
US7378417B2 (en) 2008-05-27
TWI301835B (en) 2008-10-11
AR049521A1 (es) 2006-08-09
AU2005254657B2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20081428L (no) Tetrahydrokinolinoner og anvendelse derav som modulatorer av metabotrope glutamatreseptorer
NO20073019L (no) Pyrasolonforbindelser som metabotrope glutamatreseptor-antagonister for behandlingen av nevrotiske og psykiatriske lidelser
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20080391L (no) Pyrazolbaserte LXR modulatorer
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20072965L (no) Potentiatorer av glutamatreceptorer
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
TW200728307A (en) Novel spirochromanone derivatives
NO20066055L (no) Pyridinderivater
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
WO2005123703A8 (fr) Nouveauc derives alkynyl servant de modulateurs de recepteurs de glutamate metabotropiques
NO20076478L (no) Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
WO2007078523A3 (fr) Composes d'oxazolidinone et leur utilisation en tant que potentialisateurs de recepteur de glutamate metabotropique
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20054856D0 (no) 4-anilo-kinazolinderivater som antiproliferative midler
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20082939L (no) Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20073287L (no) 2,5 og 2,6-disubstituerte benzazol-analoger som proteinkinaseinhibitorer
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application